Segment Information (Details)	3 Months Ended
	Dec. 31, 2025 USD ($) segment	Dec. 31, 2024 USD ($)
Segment Information
Number of reportable segment | segment	1
Segment loss before income taxes
Revenues, net	$ (1,207,833)
Cost of revenues	29,626
Gross profit	(1,237,459)
Research and development expenses
Research and Development Expense, Total	3,634,352	$ 9,660,150
Selling, general and administrative expenses
Total selling, general and administrative expenses	8,612,141	11,946,702
Loss from operations	$ (13,483,952)	(21,606,852)
Segment Reporting, Other Segment Item, Composition, Description	Other segment items included in segment loss includes loss on equity method investment, interest income, interest expense, loss from change in fair value of promissory notes, warrant related expenses, warrant inducement expenses, and gain from change in fair value of warrant liability
Development and commercialization of ONS-5010/LYTENAVA
Segment loss before income taxes
Revenues, net	$ (1,207,833)
Cost of revenues	29,626
Gross profit	(1,237,459)
Research and development expenses
ONS-5010/LYTENAVA development	2,594,912	8,725,849
Compensation and related benefits	614,534	569,127
Stock-based compensation	97,818	110,029
Other research and development	327,088	255,145
Research and Development Expense, Total	3,634,352	9,660,150
Selling, general and administrative expenses
Professional fees	1,247,517	2,321,458
Compensation and related benefits	914,465	2,780,189
Stock-based compensation	783,332	3,562,391
Europe launch expenses	4,800,734	2,466,342
Facilities, fees and other related costs	866,093	816,322
Total selling, general and administrative expenses	8,612,141	11,946,702
Loss from operations	(13,483,952)	(21,606,852)
Other segment items	(9,574,183)	38,984,466
Loss before income taxes	$ (23,058,135)	$ 17,377,614